Thomas Jefferson University

Jefferson Digital Commons
Department of Emergency Medicine Faculty
Papers

Department of Emergency Medicine

12-18-2019

Clinical significance of obstructive sleep apnea in patients with
acute coronary syndrome in relation to diabetes status.
Xiao Wang
Capital Medical University

Jingyao Fan
Capital Medical University

Yunhui Du
Beijing Institute of Heart

Changsheng Ma
Capital Medical University

Xin-Liang
Follow thisMa
and additional works at: https://jdc.jefferson.edu/emfp

Thomas Jefferson University
Part of the Endocrinology, Diabetes, and Metabolism Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Wang, Xiao; Fan, Jingyao; Du, Yunhui; Ma, Changsheng; Ma, Xin-Liang; Nie, Shaoping; and Wei,
Yongxiang, "Clinical significance of obstructive sleep apnea in patients with acute coronary
syndrome in relation to diabetes status." (2019). Department of Emergency Medicine Faculty
Papers. Paper 99.
https://jdc.jefferson.edu/emfp/99
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Emergency Medicine Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Xiao Wang, Jingyao Fan, Yunhui Du, Changsheng Ma, Xin-Liang Ma, Shaoping Nie, and Yongxiang Wei

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/emfp/99

Original research

Clinical significance of obstructive sleep
apnea in patients with acute coronary
syndrome in relation to diabetes status
Xiao Wang,1 Jingyao Fan,1 Yunhui Du,2 Changsheng Ma,3 Xinliang Ma,4
Shaoping Nie  ,1 Yongxiang Wei5

To cite: Wang X, Fan J, Du Y,
et al. Clinical significance
of obstructive sleep apnea
in patients with acute
coronary syndrome in
relation to diabetes status.
BMJ Open Diab Res Care
2019;7:e000737. doi:10.1136/
bmjdrc-2019-000737
►► Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
bmjdrc-2019-000737).

SN and YW contributed equally.
Received 5 July 2019
Revised 17 October 2019
Accepted 23 November 2019

© Author(s) (or their
employer(s)) 2019. Re-use
permitted under CC BY.
Published by BMJ.
For numbered affiliations see
end of article.
Correspondence to
Dr Shaoping Nie;
spnie@ccmu.e du.cn
Dr Yongxiang Wei;
weiyongxiang@vip.s ina.com

Abstract

Objective The prognostic significance of obstructive sleep
apnea (OSA) in patients with acute coronary syndrome
(ACS) according to diabetes mellitus (DM) status remains
unclear. We aimed to elucidate the association of OSA with
subsequent cardiovascular events in patients with ACS
with or without DM.
Research design and methods In this prospective cohort
study, consecutive eligible patients with ACS underwent
cardiorespiratory polygraphy between June 2015 and May
2017. OSA was defined as an Apnea Hypopnea Index ≥15
events/hour. The primary end point was major adverse
cardiovascular and cerebrovascular events (MACCEs),
including cardiovascular death, myocardial infarction,
stroke, ischemia-driven revascularization, or hospitalization
for unstable angina or heart failure.
Results Among 804 patients, 248 (30.8%) had DM and
403 (50.1%) had OSA. OSA was associated with 2.5 times
the risk of 1 year MACCE in patients with DM (22.3% vs
7.1% in the non-OSA group; adjusted HR (HR)=2.49, 95%
CI 1.16 to 5.35, p=0.019), but not in patients without DM
(8.5% vs 7.7% in the non-OSA group, adjusted HR=0.94,
95% CI 0.51 to 1.75, p=0.85). Patients with DM without
OSA had a similar 1 year MACCE rate as patients without
DM. The increased risk of events was predominately
isolated to patients with OSA with baseline glucose or
hemoglobin A1c levels above the median. Combined OSA
and longer hypoxia duration (time with arterial oxygen
saturation <90%>22 min) further increased the MACCE
rate to 31.0% in patients with DM.
Conclusions OSA was associated with increased risk of
1 year MACCE following ACS in patients with DM, but not
in non-DM patients. Further trials exploring the efficacy of
OSA treatment in high-risk patients with ACS and DM are
warranted.

Introduction
Type 2 diabetes mellitus (DM) is associated
with extensive coronary atherosclerosis1 and
accelerated plaque progression.2–4 Compared
with non-
diabetics, patients with DM are
known to have a higher risk of recurrent
cardiovascular events after acute coronary
syndromes (ACS).5–7 Obstructive sleep apnea
(OSA) is an increasingly recognized chronic
disorder in patients with ACS, with reported
incidence of 36% to 63% across various

Significance of this study
What is already known about this subject?
►► Prior reports indicated that obstructive sleep apnea

(OSA) may be associated with increased risk of recurrent cardiovascular events after acute coronary
syndrome (ACS).
►► Whether the prognostic significance of OSA in patients with ACS may be modified by diabetes mellitus (DM) status remains unclear.

What are the new findings?
►► In this prospective cohort study involving 804 pa-

tients with ACS, OSA was associated with 2.5 times
the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with DM,
but not in patients without DM. patients with DM
without OSA had a similar 1 year MACCE rate as patients without DM.
►► The increased risk of adverse events was predominately isolated to patients with OSA with poor glucose control.

How might these results change the focus of
research or clinical practice?
►► The present study showed that OSA was only asso-

ciated with increased risk of adverse events following ACS in patients with DM, therefore representing
a high-risk subset most likely to respond to the
intervention.
►► Future trials evaluating the effects of OSA treatment
in patients with DM and ACS are needed.

ethnicities.8 Recent evidence indicates OSA
initiates and exacerbates coronary atherosclerosis,9–11 and predicts adverse cardiovascular
outcomes post-ACS in the long run.12–16 Also,
studies have shown the potential interaction
between OSA and DM in glycemic control and
the development of chronic diabetic complications.17–20 Whether the prognostic significance of OSA in patients with ACS would vary
according to DM status has not been characterized. Given the shared mechanisms by
OSA and DM in promoting atherosclerosis,
we hypothesized that concomitant OSA and

BMJ Open Diab Res Care 2019;7:e000737. doi:10.1136/bmjdrc-2019-000737

1

BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000737 on 18 December 2019. Downloaded from http://drc.bmj.com/ on January 21, 2020 at Thomas Jefferson University.
Protected by copyright.

Open access

DM might exert a synergistic deleterious effect increasing
future cardiovascular risk. Therefore, we performed a
large prospective cohort study and elucidated the association of OSA with subsequent cardiovascular events in
patients with ACS in relation to diabetes status.
Research design and methods
Study design and participants
This was a prospective cohort study to evaluate the impact
of OSA on cardiovascular outcomes in patients presenting
with ACS stratified by diabetes. The study design has
been described previously.21 In brief, from June 2015
to May 2017, a total of 899 patients aged 18 years to 85
years and admitted for ACS were consecutively enrolled
and received overnight sleep study in the Emergency
and Critical Care Center of Beijing Anzhen Hospital,
Capital Medical University. Exclusions included cardiogenic shock (n=5), cardiac arrest (n=6), malignancy
(n=8), and failed sleep study (patients without adequate
and satisfactory signal recording, n=13). This left 867
patients with a successful sleep study. Next, patients with
predominantly central sleep apnea (≥50% central events
or a central Apnea Hypopnea Index (AHI) ≥10/hours,
n=20) and those receiving regular continuous positive
airway pressure (CPAP) therapy (>3 months, n=10) after
discharge were excluded. Thirty-three patients were lost
to follow-up and were excluded from the analysis. The
final cohort included 804 patients. This study conformed
to the STrengthening the Reporting of OBservational
studies in Epidemiology guidelines, and was conducted
in accordance with the amended Declaration of Helsinki.
All patients provided written informed consent.
All patients received standard care during hospitalization
according to current guidelines.22 23 Type 2 DM was identified by patient history, supported by treatment details.
Glucose and hemoglobin A1c (HbA1c) levels were obtained
from non-fasting venous blood samples at admission. We
described clinical, demographic, angiographic and procedural characteristics for each group according to DM status.
Overnight sleep study
The diagnosis of OSA was assessed by an overnight portable
cardiorespiratory polygraphy (ApneaLink Air, Resmed,
Australia) after clinical stabilization during hospitalization
(median 2 days (1 to 3 days) after admission). Sleep studies
were scored according to the American Academy of Sleep
Medicine 2007 guidelines. Sleep studies of <3 hours of
satisfactory signal recording were considered invalid and
excluded from analysis. All studies were scored manually
twice (by XW and JF), both of whom were blinded to the
demographic and clinical characteristics. Further analysis
was performed in cases of discrepancy by a senior consultant in sleep medicine (YW). Nasal airflow, thoracoabdominal movements, pulse oximetry, and snoring episodes were
recorded. An apnea was defined as total cessation of airﬂow
for ≥10 s (obstructive if thoracoabdominal movement was
present, and central if thoracoabdominal movement was
2

absent). A hypopnea was defined as an airflow reduction
of 30% for ≥10 s and was associated with a drop in arterial
oxygen saturation (SaO2) >4%. The total AHI was defined
as the number of apneas and hypopneas per hour of total
recording time. OSA was defined as AHI ≥15 events/hour.
Patients with AHI <15 events/hour were considered as the
non-OSA group. Patients with OSA (AHI ≥15), particularly
those with excessive daytime sleepiness, were referred to
the sleep center for further evaluation.
End points
The primary end point was major adverse cardiovascular and
cerebrovascular event (MACCE), defined as a composite of
cardiovascular death, myocardial infarction, stroke, ischemia-
driven revascularization, or hospitalization for unstable
angina or heart failure. Secondary end points included the
components of primary end point, all-cause death, repeat
revascularization, and a composite of all events. All end
points were deﬁned according to the proposed deﬁnitions
by the Standardized Data Collection for Cardiovascular
Trials Initiative.24 Patients were followed up from the time of
the sleep study and at 1 month, 3 months, 6 months, 1 year,
and every 6 months thereafter. Clinical events were collected
via clinic visit, medical records, or telephone calls and led by
an investigator (SN) who was blinded to the patients’ sleep
results. All clinical events were independently adjudicated
by the clinical event committee blinded to the OSA and DM
status. The committee also reviewed the source documents
and established the necessity for hospital admission and/or
revascularization.
Statistical analyses
We reported the impact of OSA on MACCE and other
cardiovascular events by DM status, the median of serum
glucose (5.9 mmol/L), and the median of HbA1c (6.0%).
Kaplan-Meier curves were plotted in OSA and non-OSA
groups stratified by DM status, dichotomized serum
glucose and HbA1c, and compared by log-rank test. The
relationship between OSA and the end points by DM
status were analyzed by Cox proportional hazard models.
Baseline variables that were considered clinically relevant
or that showed a univariate relationship with outcome
were entered into multivariable Cox regression models.
Variables for inclusion were carefully chosen, given the
number of events available, to ensure parsimony of the
final models. If a patient experienced more than one
event, only the first event was included in the analysis.
Adjusted HR with 95% CI was calculated.
Receiver operating curve (ROC) analyses were
performed to identify parameters of OSA to predict
MACCE in patients with DM. The optimal cut-off value
was estimated by area under the curve (AUC) via Youden’s Index (the maximum value of (sensitivity+specificity − 1)). We calculated event rates based on single or
combined OSA characteristics.
Continuous variables were presented as mean±SD or
median (first and third quartiles), and were compared
by Student’s t-test or Mann-Whitney U test. Categorical
BMJ Open Diab Res Care 2019;7:e000737. doi:10.1136/bmjdrc-2019-000737
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variables were shown as the number (percentage), and
were compared using χ2 statistics or Fisher’s exact test,
when appropriate. All analyses were conducted with SPSS
V.22.0 (IBM SPSS, Armonk, New York, USA). A two-sided
p value<0.05 was considered statistically significant.
Results
Patients
A total of 804 patients (82.6% male; 57.5±10.2 years)
was included in the final analysis. Of these, 248 (30.8%)
had DM and 403 (50.1%) had OSA. Patients with DM
were older, more likely to be female, and had a higher
incidence of hypertension and hyperlipidemia, but were
less likely to be current smokers. The prevalence of
OSA was similar in both DM and non-DM groups. Sleep
study results were comparable between DM and non-DM
patients (online supplementary eTable 1).
The baseline characteristics of OSA and non-
OSA
groups according to DM status are presented in table 1
and online supplementary eTable 2. Patients with OSA
exhibited higher body mass index and waist-to-hip ratio
in both subgroups. Baseline glucose and HbA1c levels
tended to be higher in patients with OSA, irrespective
of DM status. Multivessel disease was more frequent in
the OSA group compared with the non-OSA group, with
numerically more percutaneous coronary intervention
(PCI) procedures in the OSA group. Other information
was generally well matched between OSA and non-OSA
patients in the DM and non-DM subgroups.
Outcomes of OSA versus non-OSA patients in relation to
diabetes status and glucose control
Among patients with DM, the presence of OSA was strongly
associated with a higher rate of MACCE compared with
patients without OSA (22.3% vs 7.1%; HR=2.89, 95% CI
1.36 to 6.17, p=0.006). In contrast, the incidence of
MACCE was similar between OSA and non-OSA groups
in patients without DM (8.5% vs 7.7%; HR=1.06, 95% CI
0.59 to 1.90, p=0.85; table 2, figures 1A and 2). A similar
finding was observed in multivariable Cox regression analysis (table 2). Patients with DM without OSA had a similar
1 year rate of MACCE as all patients without DM (7.1% vs
8.1%; HR=0.97, 95% CI 0.47 to 1.98, p=0.93). There was
also no significant difference in the incidence of MACCE
in DM and non-DM patients without OSA (7.1% vs 7.7%;
HR=0.99, 95% CI 0.45 to 2.15, p=0.97). Conversely, in
patients with OSA, the 1 year MACCE rate was greater in
patients with DM compared with non-DM patients (22.3%
vs 8.5%; HR=2.70, 95% CI 1.56 to 4.67, p<0.001). There
was a trend towards increased risk of hospitalization for
unstable angina in OSA versus non-OSA groups in patients
with DM (table 2). Other crude number of events are listed
in online supplementary eTable 3.
For patients with glucose levels above the median of
5.9 mmol/L, the presence of OSA was associated with
a higher incidence of MACCE compared with patients
without OSA (17.4% vs 6.8%; HR=2.36, 95% CI 1.25 to
BMJ Open Diab Res Care 2019;7:e000737. doi:10.1136/bmjdrc-2019-000737

4.45, p=0.008; figures 1B and 2). Likewise, an increased
risk of MACCE was observed in the OSA group among
patients with HbA1c levels above the median of 6.0%
(18.4% vs 8.3%; HR=2.03, 95% CI 1.11 to 3.70, p=0.022;
figures 1C and 2). In contrast, there were no significant
differences in MACCE rates among patients with glucose
or HbA1c lower than median levels (figure 2).
OSA-related characteristics to predict MACCE in patients with
DM
ROC analysis was performed to identify OSA-
related
characteristics predictive of MACCE in patients with DM.
The minimum SaO2 and the duration of time with SaO2
<90% (TSA90) that predicted MACCE was a cut-off value
of 80% (AUC=0.603; p=0.048) and 22 min (AUC=0.639;
p=0.01), respectively. The rate of MACCE based on single
or combined OSA characteristics is shown in figure 3.
The MACCE rate increased to 31.0% with concomitant
OSA and TSA90 >22 min, compared with 9.8% when both
were absent (HR=3.39, 95% CI 1.73 to 6.66, p<0.001).
Discussion
The present analysis reveals a synergistic relationship
between DM and OSA, such that patients with DM and
OSA had a 2.5-fold higher rate of MACCE compared with
patients with DM but without OSA after ACS onset. In
contrast, among non-DM patients, the incidence of MACCE
was similar between the OSA and non-OSA groups. The
increased risk of adverse events was predominately isolated
to OSA patients with poor glucose control. The presence
of OSA combined with increased hypoxia duration further
exacerbated this risk in patients with DM.
Several small observational studies have demonstrated
the association between OSA and increased risk of adverse
outcomes following ACS.12–14 Our study extends prior analysis by focusing on the role of OSA in a high-risk subset of
patients with DM. The prevalence of OSA is high in patients
with DM;18 25 26 both comorbidities accelerate progression
of atherosclerosis,2 10 predisposing to recurrent events in
those that develop ACS. In the present study, the presence
of OSA significantly predicted subsequent cardiovascular
events in patients with DM, but not in non-DM patients
(consistent with the Sleep and Stent Study).27 Moreover,
our study provided detailed information regarding glucose
control and found that the increased risk of MACCE was
observed only in patients with OSA with higher glucose
or HbA1c levels. These results indicate that patients with
combined OSA and DM represent a very high-risk group
for future adverse events.
Emerging evidence has demonstrated a close relationship between OSA and incident diabetes.28 29
OSA-mediated intermittent hypoxemia and sleep fragmentation are likely contributing factors leading to abnormal
glucose metabolism. Mechanistically, recurrent cycles of
hypoxemia with reoxygenation promote oxidative stress,
systemic inflammation, and endothelial dysfunction, all
implicated in the pathogenesis of diabetes and related
3
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664 (82.6)

 Male

530 (65.9)

210 (26.1)

76 (9.5)

118 (14.7)

141 (17.5)

11 (1.4)

 Hyperlipidemia

 Prior stroke

 Prior myocardial infarction

 Prior PCI

 Prior CABG

6.0 (5.6 to 6.9)

2.3 (0.8 to 8.6)

60 (55 to 65)

 Hemoglobin A1c, %

 Hs-CRP, mg/L

 LVEF, %

203 (25.2)

254 (31.6)

 NSTEMI

 STEMI

786 (97.8)

61.2 (481/786)

490 (60.9)
80 (10.0)

 Coronary angiography

 Multivessel disease

 PCI
 CABG

Procedures

347 (43.2)

 Unstable angina

Diagnosis

5.9 (5.3 to 7.3)

 Glucose, mmol/L

Baseline tests

110 (13.7)

406 (50.5)

  Current

  Previous

288 (35.8)

  No

 Smoking

Medical history

74 (61.2)
14 (11.6)

88/119 (73.9)

119 (98.3)

37 (30.6)

25 (20.7)

59 (48.8)

60 (55 to 65)

2.7 (1.0 to 8.9)

7.8 (6.7 to 9.2)

8.5 (6.8 to 11.0)

16 (13.2)

49 (40.5)

56 (46.3)

6 (5.0)

27 (22.3)

20 (16.5)

20 (16.5)

43 (35.5)

92 (76.0)

66 (52.0)
17 (13.4)

69/123 (56.1)

123 (96.9)

27 (21.3)

34 (26.8)

66 (52.0)

63 (57 to 66)

1.7 (0.7 to 4.8)

7.2 (6.4 to 8.4)

7.4 (6.2 to 9.3)

17 (13.4)

61 (48.0)

49 (38.6)

2 (1.6)

24 (18.9)

22 (17.3)

17 (13.4)

41 (32.3)

95 (74.8)

40 (38 to 42)

 Hypertension

41 (39 to 43)

40 (38 to 42)

26.1±3.1

 Neck circumference, cm

27.4±3.0

97 (76.4)

58.7±9.7

Non-OSA (n=127)

0.98 (0.96 to 1.02) 0.99 (0.96 to 1.03) 0.98 (0.95 to 1.01)

 BMI, kg/m

91 (75.2)

59.4±9.6

OSA (n=121)

 Waist-to-hip ratio

26.7±3.6

57.5±10.2

Demographics
 Age, years

2

All (n=804)

Diabetes (n=248)

0.15
0.67

0.004

0.68

0.20

0.14

0.03

0.006

0.008

0.44

0.16

0.51

0.87

0.49

0.59

0.82

0.003

0.009

0.001

0.83

0.54

P value

Baseline patient characteristics in the OSA versus non-OSA groups according to diabetes status

Variables

Table 1

188 (66.7)
23 (8.2)

177/278 (63.7)

278 (98.6)

96 (34.0)

66 (23.4)

120 (42.6)

60 (56 to 65)

3.0 (1.1 to 11.6)

5.8 (5.5 to 6.1)

5.7 (5.2 to 6.3)

40 (14.2)

153 (54.3)

89 (31.6)

3 (1.1)

56 (19.9)

41 (14.5)

21 (7.4)

64 (22.7)

183 (64.9)

41 (39 to 43)

0.99 (0.96 to 1.02)

27.7±3.7

251 (89.0)

56.9±10.4

OSA (n=282)

No diabetes (n=556)

163 (59.5)
26 (9.5)

147/266 (55.3)

266 (97.1)

94 (34.3)

78 (28.5)

102 (37.2)

60 (55 to 65)

1.9 (0.6 to 6.8)

5.7 (5.4 to 6.1)

5.5 (5.1 to 6.1)

37 (13.5)

143 (52.2)

94 (34.3)

0 (0.0)

34 (12.4)

35 (12.8)

18 (6.6)

62 (22.6)

160 (58.4)

39 (37 to 41)

0.98 (0.93 to 1.01)

25.6±3.5

225 (82.1)

56.5±10.3

Non-OSA (n=274)

Continued

0.08
0.58

0.046

0.22

0.31

0.92

0.001

0.02

0.07

0.79

0.25

0.02

0.55

0.69

0.99

0.12

<0.001

0.001

<0.001

0.02

0.64

P value
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Continued
Diabetes (n=248)

91 (75.2)

720 (89.6)

611 (76.0)

564 (70.1)
762 (94.8)

 
β-blockers

 ACEIs/ARBs
 Statins

96 (75.6)
116 (91.3)

97 (76.4)

111 (87.4)

116 (91.3)

Non-OSA (n=127)

0.22
0.38

0.83

0.80

0.72

P value

208 (73.8)
271 (96.1)

222 (78.7)

262 (92.9)

269 (95.4)

OSA (n=282)

No diabetes (n=556)

177 (64.6)
261 (95.3)

201 (73.4)

240 (87.6)

257 (93.8)

Non-OSA (n=274)

0.02
0.63

0.14

0.03

0.41

P value

0.06
0.61

2.75 (0.28 to 26.72)
3.98 (0.44 to 35.73)
1.52 (0.50 to 4.66)
2.49 (0.97 to 6.38)
–
1.81 (0.67 to 4.90)
2.89 (1.40 to 5.93)

 Myocardial infarction†

 Stroke†

 Ischemia-driven revascularization

 Hospitalization for unstable angina

 Hospitalization for heart failure†

All repeat revascularization

Composite of all events

2.52 (1.21 to 5.22)

1.86 (0.68 to 5.14)

–

2.41 (0.93 to 6.26)

1.50 (0.48 to 4.68)

–

–

0.02

0.01

0.23

–

0.07

0.49

–

–

–

1.06 (0.59 to 1.90)

1.02 (0.62 to 1.67)

1.13 (0.56 to 2.28)

0.64 (0.11 to 3.85)

1.56 (0.71 to 3.40)

1.64 (0.55 to 4.89)

0.95 (0.13 to 6.74)

0.16 (0.02 to 1.31)

–

0.94

0.74

0.63

0.27

0.38

0.96

0.09

0.25

0.85

P value

0.95 (0.56 to 1.62)

1.08 (0.51 to 2.28)

–

1.45 (0.64 to 3.33)

1.35 (0.42 to 4.30)

–

–

–

0.94 (0.51 to 1.75)

Adjusted HR*
(95% CI)

*Model adjusted for age, sex, body mass index, hypertension, and diabetes mellitus, clinical presentation (acute myocardial infarction vs unstable angina).
†Univariate and/or multivariate Cox regression was not done due to no or few number of events.
MACCE, major adverse cardiovascular and cerebrovascular event; OSA, obstructive sleep apnea.

0.004

0.25

0.47

0.22

0.38

–

2.49 (1.16 to 5.35)

0.006
0.14

2.89 (1.36 to 6.17)
5.11 (0.60 to 43.77)

MACCE

Unadjusted HR
(95% CI)

P value

P value

No diabetes

Unadjusted HR
(95% CI)

Adjusted HR*
(95% CI)

Diabetes

Clinical outcomes in OSA versus non-OSA groups according to diabetes status

 Cardiovascular death†

Variables

Table 2

0.86

0.85

–

0.38

0.62

–

–

–

0.85

P value

Data are presented as mean±SD, median (IQR), n (%), or n/N (%).
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; Hs-CRP, high-sensitivity C reactive protein; LVEF, left ventricular
ejection fraction; NSTEMI, non-ST segment elevation myocardial infarction; OSA, obstructive sleep apnea; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial
infarction.

83 (68.6)
114 (94.2)

107 (88.4)

754 (93.8)

112 (92.6)

OSA (n=121)

 Thienopyridine

All (n=804)

 Aspirin

Medications on discharge

Variables

Table 1
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Figure 1 Kaplan-Meier curves for MACCE in OSA versus non-OSA groups according to diabetes status and glucose
control. The cumulative incidences of MACCE are shown in OSA and non-OSA groups, stratified on the basis of diabetes or
no diabetes (A), glucose level above or below the median of 5.9 mmol/L (B), and HbA1c above or below the median of 6.0%
(C). DM, diabetes mellitus; HbA1c, hemoglobin A1c; MACCE, major adverse cardiovascular and cerebrovascular event; OSA,
obstructive sleep apnea.

macrovascular and microvascular complications.30 Noteworthy, there is reverse causality between OSA and DM,
as diabetes neuropathy may worsen OSA and nocturnal
hypoxemia by affecting central control of respiration.31–33
The significant interaction between OSA and DM may
exert a synergistic effect to promote the development
and progression of atherosclerosis and increase ischemic
events in patients with ACS. In our study, the presence
of OSA and DM was associated with a very high rate of
multivessel disease. Patients with concomitant OSA and
DM were at the highest risk of incurring a MACCE. The
combination of OSA and increased hypoxia duration
increased the MACCE rate to 31.0% in patients with DM.
Specifically, most events in this study were rehospitalizations for unstable angina and repeat revascularization
(mostly attributed to non-
target vessels). Cardiovascular
death, MI, and stroke were less common. Prior studies have
6

demonstrated that long-term adverse outcomes in patients
with DM were predominantly caused by new lesions in non-
culprit vessels.34 Similarly, untreated OSA was also associated with increased risk of repeat revascularization (mainly
in non-target lesions).35 Patients with OSA and DM, given
shared mechanisms, are more prone to native plaque
progression and subsequent cardiac ischemic events.
On the other hand, patients without DM represent a
relatively low-risk subset compared with those with DM.
According to intravascular ultrasound analysis, non-
DM
patients had fewer lesions across the coronary tree and
had less necrotic core as well as a lower frequency of
thin-cap fibroatheromas, indicating a lower risk of plaque
vulnerability.36 37 Although OSA could promote oxidative
stress and inflammatory responses, resulting in endothelial dysfunction and reduction of repair capacity,38 it may
have less effect in non-DM patients. In our study, OSA was
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Figure 2 Outcomes of MACCE in OSA vs non-OSA groups
according to diabetes status and glucose control.Shown
are the crude incidences of MACCE, unadjusted HR, and
95% CI in patients with OSA and non-OSA patients in each
subgroup. HbA1c, hemoglobin A1c; MACCE, major adverse
cardiovascular and cerebrovascular event; OSA, obstructive
sleep apnea.

not associated with increased risk of cardiovascular events
following ACS in non-DM patients, a finding also observed
in another study including patients undergoing PCI.27
Thus, it is more reasonable and clinically significant to
screen for OSA in high-risk patients with ACS (DM, etc).
Currently, data from randomized controlled trials do not
support a role of CPAP for reducing cardiovascular events
among patients with established cardiovascular disease.39 40
In the RICCADSA (Randomized Intervention with Continuous Positive Airway Pressure in CAD and OSA) Study,
224 non-
sleepy patients with OSA and coronary artery
disease (CAD) were randomized to CPAP or usual care.
At a median follow-up of 57 months, no difference was
found in a composite end point of repeat revascularization,
MI, stroke, or cardiovascular death.39 The negative results

may be partly explained by the fact that patients are under
guideline-based optimal medical therapy, including intensive antiplatelet therapy, and control of blood pressure,
dyslipidemia, and glucose, which are also the intermediate
mechanisms implicated in OSA.41 More importantly, the
RICCADSA trial included the entire spectrum of patients
with CAD, with only 25% of patients having DM, thereby
limiting the sample to a potentially lower-risk group.39 In
the present study, only patients with combined DM and
OSA had a significantly increased risk of future events after
ACS, therefore representing a high-risk subset most likely to
respond to the intervention. Conversely, patients with DM
without OSA had a similar prognosis as patients without
DM (with or without OSA). The presence of OSA seems to
be a key modifier contributing to the negative effect of DM
in patients with ACS. Thus, for patients with ACS and DM,
it is important to screen for OSA and intervention may be
needed, although more trials evaluating the effects of OSA
treatment in this high-risk subgroup are warranted.
Study limitations
First, the size of the DM cohort with 248 patients was
modest. However, the primary outcome showed a significant difference between the OSA and non-OSA groups
in patients with DM. Also, the results based on glucose
and HbA1c levels were consistent with the main findings.
Second, the diagnosis of OSA was based on portable
polygraphy, a method that may underestimate AHI due
to overestimating actual sleeping time. Third, although
OSA severity may be overestimated during the acute
setting of ACS but not stable CAD,42–44 this is true for OSA
assessment in the setting of any high-risk acute disease
including heart failure. Additionally, the patients in our
study received a sleep study after clinical stabilization

Figure 3 Rate of MACCE based on single or combined OSA characteristics in patients with diabetes. The best cut-off values
of minimum SaO2 <80% and TSA90 >22 min were used in the adjusted Cox regression analysis. MACCE, major adverse
cardiovascular and cerebrovascular event; OSA, obstructive sleep apnea; SaO2, arterial oxygen saturation; TSA90, the duration
of time with SaO2 <90%.
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during hospitalization, minimizing the potential bias.
Fourth, the overall sample was predominantly male and
non-obese. Whether our findings may be extrapolated
to the female or obese population is unknown. Finally,
this study primarily recruited East-Asian patients. Studies
pertaining to other ethnicities are needed.

Conclusions
The present study demonstrated that in high-
risk
patients with ACS and DM, the presence of OSA
was associated with a higher incidence of MACCE
compared with patients without OSA. The increased
risk associated with OSA was not observed in non-DM
patients. Moreover, the prognosis of patients with DM,
but without OSA, was similar to patients without DM.
Further randomized trials exploring the efficacy of
OSA treatment in the high-risk population with both
DM and ACS are highly warranted.
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